AMC-303

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameAMC-303
Drug Alias NameAMC-303HP-558
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionCD44 antigen inhibitors
TargetsCD44 antigen
Therapy Area/IndicationsSolid tumoursEsophageal Squamous Cell Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumSpainMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAmcure Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesAbf Pharmaceutical Services GmbhHinova Pharmaceuticals (Usa) IncHinova Pharmaceuticals Inc
Inactive CompaniesAmcure Gmbh
Active IndicationsEsophageal Squamous Cell Carcinoma
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A